Report copyright - Company presentation for investors · 21 Investor Presentation FY2014 Compound AR affinity Ki (nM) Antagonism WT AR IC50 (nM) Proliferation VCaP IC50 (nM) enzalutamide 78 155 400
Please pass captcha verification before submit form
Please pass captcha verification before submit form